Ophthalmology

Despite the availability of anti-VEGF therapies, there is still a notable disease burden in older adults with vision-threatening retinal diseases.

Experts reflect on the current information available on the safety and durability of second-generation agents aflibercept 8 mg and faricimab.

Experts share their real-world experience with aflibercept 8 mg, comparing it to its predecessor, aflibercept 2 mg.

Adults with strabismus in a diverse nationwide cohort were approximately 2 to 3 times more likely to experience mental health conditions.

National data show older Americans with vision impairment were less likely to have access to digital technology than counterparts without impairments.

Each month, our editorial staff compiles a recap of the top news in ophthalmology. Our March 2024 ophthalmology month in review features a recap of the latest news from the ophthalmic pipeline.

Peter A. Campochiaro, MD, discusses the safety and tolerability of RGX-314 gene therapy in treating wet AMD and how these results inform pivotal clinical trials.

The phase 2b trial showed a statistically significant improvement of BCVA at week 52 in both the high-dose and low-dose MCO-010 cohorts compared with sham.

Positive phase 2 results from NEPTUNE represent the best treatment failure rates observed among active studies in non-infectious uveitis.

In a systematic review and meta-analysis of available data, lotilaner ophthalmic solutions outperformed placebo, with few side effects, in treating Demodex blepharitis.

A single administration of ABBV-RGX-314 was generally well tolerated, with little to no supplemental anti-VEGF injections required in most patients at two years.

Ehsan Rahimy, MD, outlines strategies for managing cases of high-risk PDR and DME, exploring new therapies and synergistic combinations with anti-VEGF and steroids for longer-lasting responses.

An expert retina specialist discusses challenges faced by DME patients showing suboptimal response to standard anti-VEGF treatment, emphasizing the need to reduce injection burden while preventing vision loss.

Ehsan Rahimy, MD, discusses challenges in managing longstanding nAMD patients rotating through anti-VEGF treatments, highlighting the promise of newer therapies like aflibercept 8mg and faricimab.

Experts expand on the discussion of first-line therapy choice, discussing how insurance mandates may alter treatment paths and the importance of catering to patient goals.

Experts discuss the importance of optimizing first-line therapies in the treatment of retinal diseases like neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

Deepak Sambhara, MD, discusses how clinical practice has responded to the introduction of aflibercept 8 mg and the significance of extended treatment intervals for patients with retinal diseases.

David M. Brown, MD, discusses the full one-year data from the PULSAR and PHOTON trials and the implications of aflibercept 8 mg for patients with AMD and DME.

NCX 470 0.1% eye drops reduced IOP more than latanoprost in individuals with open-angle glaucoma or ocular hypertension in the phase 3 Mont Blanc trial.

Retina expert shares his strategy for managing a patient recently diagnosed with nAMD who started on bevacizumab, discussing criteria for transitioning to more efficacious therapy.

Ehsan Rahimy, MD addresses barriers like step edits with bevacizumab and biosimilars in nAMD, emphasizing the impact of insurance-guided choices on treatment outcomes and advocating for a personalized approach.

Metformin demonstrated a protective effect against new-onset geographic atrophy, which persisted and was more pronounced in individuals without diabetes.

A cohort analysis in the UK observed no significant association between sildenafil use and AMD prevention in men with erectile dysfunction.

A post-hoc analysis of the Ocular Hypertension Treatment Study shows the inclusion of a PRS improved the prediction of POAG onset in patients with ocular hypertension.

Oral minocycline was not associated with a decrease in GA enlargement over 24 months, compared with the run-in phase, in a recent phase 2 nonrandomized trial.

Nesvategrast was safe and well tolerated but did not exhibit a statistically significant impact on the severity or progression of diabetic retinopathy in the phase 2 DR:EAM trial.

Study links childhood amblyopia with increased risk of cardiometabolic dysfunction in adulthood.

A water-free cyclosporine ophthalmic solution (SHR8028) more effectively improved total corneal fluorescein staining versus vehicle, but showed no superiority in dryness score, in phase 3 findings.

Published one-year results from PULSAR and PHOTON show extended dosing regimens with aflibercept 8 mg were non-inferior to aflibercept 2 mg for treating wet AMD and DME.

Continuous glucose monitoring was associated with lower odds of diabetic retinopathy development, even after adjusting for hemoglobin A1c levels.